• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider 2013 Product Image

Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider 2013

  • ID: 2569949
  • March 2013
  • Region: Global
  • 200 Pages
  • DeciBio

Next generation sequencing (NGS) is a disruptive technology that allows scientists to sequence and assemble millions to billions of short DNA reads. This technology is used for applications such as whole genome sequencing, whole exome sequencing (1-2% of the genome that actually encodes proteins) or expression profiling. NGS is the fastest growing and the most attractive segment of the $7.1B genomics space (manufacturer market). With an estimated market size of ~$1.2B in 2012, and a double digit growth rate, we forecast this market will reach $2.1B in 2015, driven by adoption in non-academic customers, especially clinical customers. NGS is poised to revolutionize not only medical research in academic laboratories and Biopharma, but also the healthcare landscape and applied markets (e.g., AgBio, food testing). The second edition of this report reviews the market size, segmentation, growth and trends of the NGS (and third generation sequencing) market.

We assess the NGS market across 5 segments: company (Illumina, Life Technologies (Ion Torrent), Roche / 454 Life Sciences, Pacific BioSciences, and Others), product type (Instrument, Reagents, Services), customer (Academia, Biopharma, READ MORE >

ABSTRACT

EXECUTIVE SUMMARY

INTRODUCTION
What’s new
Context and methodology
Genomics market overview

NEXT GENERATION SEQUENCING MARKET
Market overview
Applications
Market size and growth by product type
Market size and growth by instrument type
Market size and growth by company
Market size and growth by customer base
Market size and growth by geography
Technology trends in genomics use

COMPETITIVE ANALYSIS
Illumina
Life Technologies / Ion Torrent
Roche / 454 Life Sciences
Pacific Biosciences
BGI / Complete Genomics

DESKTOP SEQUENCER: ILLUMINA vs. ION TORRENT

NEXT GENERATION SEQUENCING IN THE CLINIC

APPENDIX
Nanopore sequencing
NGS publication analysis
DNA target enrichment
Additional NGS competitors
Platform selection criteria and unmet needs
2010 Review
Decommissioning of Sanger instruments
Helicos
Complete Genomics
Table of exhibits
Abbreviations

Table of exhibits

Exhibit 1: WW genomics market by technology (2012E)
Exhibit 2: Genomics market drivers and moderators
Exhibit 3: WW NGS market (2009-2015F)
Exhibit 4: Key NGS market drivers and moderators
Exhibit 5: NGS application classes and sub-classes
Exhibit 6: Platform fit for key experimental classes and subclasses
Exhibit 7: WW NGS market by product type (2009-2015F)
Exhibit 8: Price range of current NGS instruments
Exhibit 9: Summary of market trends by product types
Exhibit 10: WW NGS market by instrument type (2009-2015F)
Exhibit 11: Summary of market trends by experimental throughput
Exhibit 12: WW NGS market by company (2009-2015F)
Exhibit 13: WW NGS market by customer type (2009-2015F)
Exhibit 14: Summary of market trends by customer type
Exhibit 15: WW NGS market by geography (2007-2015F)
Exhibit 16: Summary of market trends by geography
Exhibit 17: Past and current cost per million base pairs
Exhibit 18: Forecasted number of genome sequenced (2009-15)
Exhibit 19: Sequenced genomes
Exhibit 20: Application fit of Illumina platforms
Exhibit 21: Specifications and costs of Illumina platforms and reagents
Exhibit 22: Capabilities of the HiSeq2000 / 2500
Exhibit 23: Comparison of HiSeq 2500 rapid run mode vs. high output mode
Exhibit 24: Recent developments for the HiSeq2000 & 2500
Exhibit 25: Capabilities of the HiSeq1000
Exhibit 26: Recent developments for the HiSeq 1000
Exhibit 27: Capabilities of the GA IIx
Exhibit 28: Recent developments for the GA IIx
Exhibit 29: Capabilities of the MiSeq
Exhibit 30: Benchmarking of MiSeq and PGM
Exhibit 31: Recent developments for the MiSeq
Exhibit 32: Application fit of Life Technologies platforms
Exhibit 33: Specifications and costs of Life Technologies platforms and associated reagents
Exhibit 34: Capabilities of the SOLiD 5500 vs 5500xl
Exhibit 35: Recent developments for SOLiD instruments
Exhibit 36: Capabilities of the Ion Torrent PGM
Exhibit 37: Recent developments for PGM instruments
Exhibit 38: Capabilities of the Ion Torrent Ion Proton
Exhibit 39: Recent developments for Ion Proton instruments
Exhibit 40: Application fit of Roche / 454 platforms
Exhibit 41: Specifications and costs of Roche / 454 platforms and associated reagents
Exhibit 42: Capabilities of the 454 GS FLX and FLX+
Exhibit 43: Recent developments for FLX / FLX+ instruments
Exhibit 44: Capabilities of the 454 GS Junior
Exhibit 45: Recent developments for GS Junior instruments
Exhibit 46: Application fit of PacBio RS vs. competitors
Exhibit 47: Specifications and costs of PacBio RS and associated reagents
Exhibit 48: Capabilities of the PacBio RS
Exhibit 49: Recent developments for PacBio RS instruments
Exhibit 50: Recent developments for Complete Genomics services
Exhibit 51: Complete Genomics CGA platform capabilities
Exhibit 52: Relative market share of desktop sequencers (2010-2015F)
Exhibit 53: Level of satisfaction with Illumina and Life Technologies desktop sequencers
Exhibit 54: Next generation sequencing methodologies
Exhibit 55: Selected launched NGS tests
Exhibit 56: WW NGS MDx market size by disease area (2009-15F)
Exhibit 57: WW NGS MDx market size by NGS approach (2009-15F)
Exhibit 58: Drivers and moderators of NGS use in clinic settings
Exhibit 59: NGS clinical workflow
Exhibit 60: Number of selected NGS publications by field of study (2008-12)
Exhibit 61: Percent of selected NGS publications by field of study (2008-12)
Exhibit 62: Target enrichment market share (2011E)
Exhibit 63: High-throughput NGS platform selection criteria
Exhibit 64: Low-throughput NGS platform selection criteria
Exhibit 65: NGS unmet needs for high throughput platforms
Exhibit 66: NGS unmet needs for low throughput platforms
Exhibit 67: Sequencing platforms by large genome center (2008)
Exhibit 68: Specifications and costs of Heliscope and associated reagents
Exhibit 69: Application fit of Heliscope platforms
Exhibit 70: Capabilities of the Heliscope
Exhibit 71: Recent development for Complete Genomics services
Exhibit 72: Complete Genomics services throughput
Exhibit 73: Complete Genomics CGA platform capabilities
Exhibit 74: Complete Genomics services pricing
Exhibit 75: Recent development for Complete Genomics services

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos